Tradestie Institutional Equity Comparison Engine

AIM vs GNPX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GNPX Overall Edge

GNPX Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Genprex, Inc. Common Stock (GNPX) driven by superior Growth & Margin, Momentum & Technical while AIM counters with relative strength in Valuation. Fundamentally, AIM trades at 2.0x Forward P/E with -11724.2% operating margin (+4.0% YoY revenue) versus GNPX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AIM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against GNPX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AIM
AIM 2.0x vs GNPX N/M Fwd P/E
Growth & Margin Winner GNPX
Op Margin -11724.2% vs 0.0% ยท YoY +4.0% vs +0.0%
Momentum & Technical Winner GNPX
1Y -91.4% vs -56.6% ยท 52W Pos 0% vs 11%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
AIM NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.11
-4.5% 1D
Market Cap $4.8M
1M Return -28.82%
1Y Return -91.38%
Forward P/E 2.0x
Unified AI Score
39.4 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
1M Return -26.77%
1Y Return -56.59%
Forward P/E N/M
Unified AI Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AIM -91.38% GNPX -56.59% Spread: +34.79 pp (GNPX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AIM TTM Op. Margin: -11724.2% GNPX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AIM vs GNPX. Trailing 12-month operating profitability (AIM -11724.2% vs GNPX 0.0%) and valuation multiples (AIM 2.0x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AIM (4) vs GNPX (4)
Institutional Metric AIM GNPX Criterion Row Winner
Market Capitalization Scale $4.8M $2.2M Larger Scale Tie
Trailing P/E Ratio Valuation 2.0x N/M Lower Multiple AIM
Forward P/E Ratio Valuation 2.0x N/M Lower Multiple AIM
Revenue Growth (YoY) Growth +4.0% +0.0% Higher Growth AIM
Operating Margin (TTM) Profitability -11724.2% 0.0% Higher Margin GNPX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2382.3% -233.7% Higher ROE GNPX
52-Week Range Position Momentum 0% ($0โ€“$2) 11% ($0โ€“$10) Stronger Trend GNPX
Beta / 30D Volatility Risk Regime 0.56ฮฒ ยท 76% Vol -4.68ฮฒ ยท 96% Vol Lower Realized Risk AIM
Unified Institutional Score Composite Signal 39.4 / 100 (SELL) 42.2 / 100 (HOLD) Higher Composite GNPX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AIM vs GNPX Buy Guide
AIM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AIM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GNPX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GNPX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AIM nor GNPX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.